anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses water soluble solid bee glue and a preparation method thereof. Edible sodium hydroxide is weighed according to certain weight percentage, and then, water is added to dissolve the edible sodium hydroxide. The edible sodium hydroxide is heated to 60 to 90 DEG C, and then, bee glue is added. The edible sodium hydroxide continues to be heated and stirred until the bee glue is totally dissolved, styrax and dragon blood are added, and the edible sodium hydroxide continues to be heated and stirred until the styrax and the dragon blood are totally dissolved. Then, redundant water is removed by evaporating, and the mixture is poured in a mould. The processes of removing water in vacuum and solidifying are carried out to obtain the water soluble solid bee glue. The water soluble solid bee glue produced by the present invention has the characteristics of convenient administration, convenient preservation and carrying and easy absorption by human bodies.
Bee Buzzy Group: Bee Buzzy was attached to the 3-6-year-old child included in this group by the researcher on the arm of the nurse to perform the phlebotomy procedure. Bee Buzzy reduces pain thanks to its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee Buzzy was tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse performed a phlebotomy.
All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
Detailed patient examination will be carried out and those satisfying inclusion criteria will be enrolled in the study. Written informed consent will be obtained and patients will be randomly allocated to two groups. Entire surgical procedure will be carried out by single operator. After complete elevation of the flap, debridement (periradicular curettage -enucleation) of the bony lesion will be performed. 3 mm root-tip resection will be performed and root end cavity will be prepared using an ultrasonic diamond-coated retrotip. Root end filling will be done with mineral trioxide aggregate (MTA). In test group The i-PRF will be produced and incorporated with collagen will be used to fill into the defect. In the control group, no guided tissue regeneration technique will be used. Flap will be re-positioned and sutured using nonabsorbable 4-0 silk sutures.Sutures will be removed 4-7 days postoperatively.
A process for producing a low endotoxin alkali chitosan, chitin or a derivative thereof comprises contacting chitosan, chitin or a derivative thereof with an alkali solution to form a mixture and leaving the mixture for less than 1 hour. Preferably, the alkali solution is from 0.01M to 1M and may be selected from sodium hydroxide, potassium hydroxide, or sodium carbonate. The mixture may be left for less than 3 minutes. The mixture may also contain a preservative selected from silver ions, zinc ions, or chlorohexadine. The process may comprise a further step of immediately drying the mixture after the addition of the alkali. An alkali chitosan may be subsequently treated with an acid to form a neutral chitosan. Alkali chitosan, neutral chitosan, and chitosan salts or other derivatives, each comprising an endotoxin concentration of less than 50 EU/g are also disclosed. The chitosan salt may be used to stem blood flow and may be incorporated into a wound dressing.
Patients are mapped to clinical trials for patient-specific clinical decision support. Systems and methods for mapping a patient to one or more clinical trials are provided. Patient data for a patient is received and encoded into a patient model for the patient. A synthetic patient is generated for each clinical trial in the set of clinical trials based on the characteristics of the participants in the clinical trial. A patient model of the patient is compared to each synthetic patient to identify a synthetic patient that matches the patient model. Based on matching the synthetic patients, the patients are mapped to one or more clinical trials in the set of clinical trials.
Phamiaceutical compositions are provided containing psilocybin, which are designed for rapid dissolution properties and immediate or rapid release. The compositions are designed for targeted release by way of: (1) stomach release; or (2) mucosal release. The compositions can be used as pre-formulations for further tableting, encapsulation, or formulating into a sublingual dosage form for oral use, designed for rapid therapeutic onset. Particularly, the compositions overcome unfavourable fommlati on characteristics of psilocybin that cause drug release variability and problems for formulating into finished dosage forms. More particularly, psilocybin is fommlated in a manner to overcome drug release variability thereby providing unifomi potency and desirable bioavailability characteristics. The compositions may be used for inducing therapeutically beneficial behaviour change in subjects with a variety of psychiatric conditions.
This is a single-center study to evaluate the clinical outcomes of Lotemax 0.5% for the treatment of Ocular inflammation associated with cataract surgery. Subjects will be screened from one to 21 days prior to initiation of dosing with the test article. Subjects who sign the informed consent document and meet all inclusion/exclusion criteria will be eligible to participate in this study. Subjects will instill one drop of Lotemax into the study (operative) eye QID for a maximum of 22 days. Dosing with test article will begin the day of surgery and for 21 days after surgery. Subjects will be seen for evaluation on Days 1, 7±1, and 21 ± 2 following surgery. Subjects will be seen for a follow-up visit on Day 42 ± 3 following surgery, about 21 days after their last dose of test article.

In addition to the test article regimen, subjects will receive Vigamox TID 3 days prior to surgery. Patients will receive one drop of Timoptic XE 0.5%, Zymaxid on the day of surgery. Postoperatively, patients will receive Vigamox TID for ten days and Bromday QD for 3 weeks.
The Department of Veterans Affairs (VA) identifies employment as a priority issue for OEF/OIF veterans. However, OEF/OIF veterans with polytrauma represent a new and unique VA sub-population. Polytraumatic injuries are more complex than injuries sustained in any previous conflict. Returning to work, therefore, may prove especially challenging. Among individuals with severe disabilities, employment outcomes are closely tied to the individual's level of success with Independent Living (IL). IL refers to the ability to reside in the community and participate in activities of choice by managing available resources, negotiating barriers and exercising self-determination. IL often is viewed as a prerequisite to employment for severely disabled individuals, because barriers and facilitators to independence at home and in the community also influence success in the workplace. Thus, IL will be a critical first step to pursuing vocational/employment goals for OEF/OIF veterans with polytrauma. To date, no published studies have investigated IL among veterans with polytrauma. This pilot study will be the first project in a line of research to promote the independence and employability OEF/OIF veterans. The goals of the study are twofold. Goal 1 of the study is to investigate the barriers and facilitators to IL identified by community dwelling OEF/OIF veterans with polytrauma, caregivers, and IL service providers, and perceptions of how these factors may affect veterans' return to work. This goal will be accomplished by using qualitative methods for data collection and analyses. Qualitative interviewing will be used to elicit the perspectives of veterans with polytrauma and caregivers living in Florida, and Florida-based Vocational Rehabilitation and Employment IL service providers. Qualitative data will be coded, and then analyzed using the constant comparative method. Goal #2 of the study is to evaluate the feasibility of using the data collection tools and procedures for a future planned study. An efficacy evaluation will be used to test and refine the data collection tools (interview guides and demographic checklists). To evaluate data collection procedures, field notes will be recorded and analyzed to identify optimal organizational procedures and time parameters to minimize subject burden. Findings will be used to plan and design a large, national study of factors affecting return to work among OEF/OIF veterans with polytrauma living throughout the United States. Findings also will be used to develop future proposals to fund longitudinal research and implementation projects to improve employability outcomes among veterans with polytrauma.
The recommended starting dose is the fixed-dose combination (FDC) standard dose (SD) tablet, containing 100 mg cedazuridine and 35 mg decitabine, once daily, Days 1 through 5 in 28-day cycles. Participants should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
Pathological germline variants (PGVs) of RAD51D increase the risk of breast and ovarian cancer. In East Asia, c.270_271dup is the most frequently detected PGV of RAD51D; however, only a few cases have been reported in Japan. We report four cancer cases with a germline RAD51D c.270_271dup PGV. Three of them (lung cancer: 2, oral cancer: 1) were incidentally identified by whole genome sequencing in patients negative for the associated cancer histories, homologous recombination (HR) deficiency, or a second hit of RAD51D in the cancer DNA. For genetic counseling, we provided information on surveillance and cascade testing based on Western guidelines. The PGVs of moderate-risk HR-related genes are difficult to detect based on phenotype, especially in male-predominant pedigrees. The current spread of cancer genomic analysis will increase opportunities for incidental variant identification. The establishment of Japanese guidelines is expected to aid in the management of PGV carriers of moderate-risk genes.
The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains \> 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
System comprising means 2 for transmitting nutritional information from a food item 1; means for transmitting the nutritional information to a server at a time t1 and for transmitting physiological information of a user following consumption of the food item to the server at a time t2; and means for providing updated physiological information to the user at a time t3 based on the nutritional information and the physiological information. May comprise means for providing updated physiological information to the user based on information provided by the user at a time t4. The means for transmitting nutritional information from a food item may comprise a NFC transmitter, which may be integrated into packaging of the food item. The nutritional information may comprise a food type, ingredients, calorie, macronutrient or micronutrient content of the food item. The means for transmitting the nutritional information to the server and for providing physiological information of the user may comprise a smart phone, smart watch, wearable smart device, smart clothing, smart shoes, or wearable body sensor. Also provided is a smart device configured to receive nutritional information from a food item without user input and transmit the information to a server.
Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
Mice with endothelial-cell-specific overexpression of C-type natriuretic peptide (E-CNP Tg mice) were shown to be protected against hepatic fibrosis and inflammation induced by high fat diet (HFD) feeding, with improved insulin sensitivity and attenuated weight gain. A recently developed high-fat, high-fructose, high-cholesterol diet (HFFCD) is considered to be a superior model to HFD, owing to the resemblance to human non-alcoholic steatohepatitis (NASH). In this study, we therefore aimed to reveal whether these previous findings with E-CNP Tg mice on HFD can be observed in a newly developed NASH model. Patients with NASH have been suggested to be at higher risk of developing chronic kidney disease, so we also assessed the kidney histology of these mice. After 8 months of HFFCD feeding, the livers of E-CNP Tg mice and controls showed progressive fibrosis, which resembled the features of human NASH. However, no significant differences were observed in NAFLD activity scores between E-CNP Tg mice and controls, although there was a tendency for improvement in E-CNP Tg mice. The reduced levels of GCB, a receptor for CNP, may have weakened the action of CNP in the current model. In the kidneys, HFFCD showed glomerular hypertrophy and tubular atrophy in the cortical region, which were suppressed in E-CNP Tg mice. The present study did not prove the therapeutic effect of CNP on NASH in the HFFCD model, but provided evidence of its potential beneficial effects on NASH-associated renal damage.
The present invention relates to an external preparation of cetirizine hydrochloride of antihistamine medicaments, namely a gelling agent and a preparation technology thereof, which belongs to the technical field of medicaments. The cetirizine hydrochloride is a medicament clinically and generally used. The existing preparation is an oral preparation such as tablets, capsules, solution, etc. Because the cetirizine hydrochloride has a central inhibition function, a patient orally takes the medicament and has adverse reactions such as somnolence, vertigo, headache, etc. The cetirizine hydrochloride is used as a main medicament; different auxiliary materials are added and prepared into the gelling agent; the administration is carried out by skin or mucosae; the external preparation avoids a first pass effect on a liver and stimulation to gastrointestinal tracts due to oral administration, reduces a systemic blood medical concentration, reduces the central inhibition function, and enhances the medical concentration of local affected positions such as the skin, the nasal mucous membranes, etc. Moreover, the external preparation has the advantages of the reduction of administration times, convenient use, the enhancement of the compliance of patient medication and the like, and provides a new administration preparation for the clinical application of cetirizine.
Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
MOTS-c, a mitochondrial-derived peptide, acts as a systemic hormone and MOTS-c level is inversely correlated with markers of obesity. Obesity is a risk factor for male reproductive physiology and is expressed as an important cause of infertility. In this study, we aimed to determine the effects of MOTS-c, which has been proven in the hypothalamus and testicles, on the actors involved in the reproductive axis. In the study, 80 male Wistar-Albino rats were divided into two main groups, obese and non-obese (n = 40). Rats in the first main group were fed with fatty diet feed and obesity was induced. The second main group was fed with normal diet feed. Each main group was divided into 4 subgroups (Control, Sham, 10 and 100 µM MOTS-c). The lateral ventricles of the animals in the treatment groups were infused with 10 and 100 µM MOTS-c (solvent in Sham group) for 14 days. At the end of the experiment, hypothalamic Gonadotropin-Releasing Hormone (GnRH) gene expression level, serum testosterone, Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels were determined. MOTS-c infusion caused an increase in GnRH mRNA, protein expression levels and serum testosterone, LH and FSH levels in obese and non-obese rats (p < 0.05). MOTS-c administration more significantly upregulated hormone levels in non-obese rats (p < 0.05). MOTS-c administration increases these hormones, suggesting that MOTS-c may stimulate the reproductive axis. Our results reveal that MOTS-c plays a role in the central regulation of reproduction, as well as causes increased LH, FSH and testosterone release.
Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
A nucleic acid delivery system that offers, in one system, a combination of high encapsulation efficiency, rapid release kinetics and preservation of DNA in supercoiled form is provided. The nucleic delivery system comprises nucleic acid molecules, such as deoxyribonucleic acid (DNA), encapsulated in biodegradable microspheres, and is particularly suited for delivery DNA vaccines. The ivnention futher provides a method for encapsulating nucleic acid molecules in microspheres. The invention additionally provides a composition comprising nucleic acid molecules encapsulated in microspheres produced by a method of the invention, and a method for delivering a nucleic acid molecule to a subject. The invention futher provides an adjuvant for modulating the immunostimulatory efficacy of microspheres encapsulating nucleic acid molecules comprising an aminoalkyl glucosaminide 4-phosphate (AGP). The invention also provides a method for modulating the immunostimulatory efficacy of microspheres encapsulating nucleic acid molecules.
Under aseptic technique, all the patients will receive US-guided femoral, obturator and sciatic nerve blocks using a single puncture point. All blocks will be performed by an expert anesthetist. The femoral nerve will be blocked lateral to the femoral artery. The obturator nerve will be blocked after it exits the obturator canal (deep to pectineus muscle). While the sciatic nerve will be blocked deep (posterior) to the inferior border of quadratus femoris muscle. The motor block of the femoral, obturator and sciatic nerves and sensory block of the lateral femoral cutaneous nerve (LFCN) will be assessed before shifting the patient to the operating room.

The performance time, patient discomfort, technique success rate, the associated successful LFCN block and any complication will be recorded by the assistant. All patients were assessed neurologically before discharge and during the physiotherapy visits for 3 weak after surgery.
Treatments for locally advanced cervical cancer, defined as International Federation of Gynecology and Obstetrics (FIGO) stage Ib2-III include primary surgery, neoadjuvant chemotherapy and concurrent chemo-radiotherapy (CCRT). In many countries, CCRT is accepted as the standard therapy for such tumors. However, each of these therapies has both advantages and disadvantages, however, more recently it has been given using neoadjuvant chemotherapy with intravenous irinotecan hydrochloride (CPT-11) and cisplatin. DNA topoisomerases are enzymes that regulate and control DNA topology. Topoisomerase 1 catalyzes the transient cutting of a single DNA strand, the passage of another DNA strand through the break and then resealing of the DNA break. Camptothecin (CPT), an antitumor alkaloid isolated from Camptotheca acuminata, interferes with DNA topoisomerase 1 function. Cisplatin (cis-dichlorodiammineplatinums II) is a first generation platinum compound. Platinum-based NACT followed by radical hysterectomy has been proposed as an alternative approach to radiotherapy or CCRT in locally advanced cervical cancer, especially of squamous cell histology, with objective response rates ranging from 69.4% to 90.2%, pathological optimal response rates ranging from 21.3% to 48.3%, 5-year disease free survival (DFS) rates ranging from 55.4% to 71% and 5-year overall survival(OS) rates ranging from 58.9% to 81%, respectively.
Dental prostheses or like appliances are composed at least in part of polyethylene of density greater than 0.930 gram per cc. at 20 DEG C., and a melt viscosity of from 1 X 104 to 1 X 106 poises at 140 DEG C.  They may contain a non-toxic, tasteless surface-active agent such as a condensation product of 1 mol. dodecanol with from 8 to 12 mols. of ethylene oxide, anti-oxidizing agents, colouring agents and fillers. Specification 721,326, [Group V], is referred to.ALSO:Dental protheses or like appliances are composed of at least in part, of polythene having a density greater than 0,930 grams per c.c. at 20 DEG C., and a melt viscosity of from 1 x 104 to 1 x 106 poises at 190 DEG C.  Dentures are prepared by a method as described in Specification 721,326, or by packing two halves of a mould with softened polyethylene, further melting by an infra-red lamp, and clamping the mould together and finally cooling, or by forming a preform of the denture or appliance, placing it in a mould, softening by infra-red heat and closing the mould to complete the shaping.